Purpose
To estimate the public health impact and cost-effectiveness of combining 2 or 4 valent Shigella antigens with existing Pneumococcal Conjugate Vaccine (PCV), vaccines in contrast with higher valency PCV vaccines.
Grantee
Division
Global Health
Date
JULY 2026
Region served
GLOBAL
Committed amount
$165,000
Grant topic
Vaccine Development
Duration (months)
12
Grantee location
Atlanta, Georgia, United States
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.